The expression of hypoxia inducible factor 1-alpha in lung cancer and its correlation with P53 and VEGF

Abstract

To investigate the expression of hypoxia inducible factor 1-alpha (HIF-1α) and its correlation with P53 and vascular endothelial growth factor (VEGF), immunohistochemical technique was employed to detect the protein expressions of HIF-1α, P53 and VEGF in specimens from 57 patients with lung cancer. The results indicated that the total positive proportion of HIF-1α expresion was 63% and the HIF-1α expression was more frequent in bronchiole-alveolar carcinoma (86%) than in other lung cancer. There was a strong association of HIF-1α with VEGF and P53 protein expressions. It is concluded that HIF-1α overexpression is a common event in lung cancer, which may be related to the up-regulation of the angiogenic factor VEGF and oncogene mutant P53 protein.

Keywords

hypoxia inducible factor-1alpha / P53 / vascular endothelial growth factor / lung cancer

References

[1] WangG L, JiangB H, RueE A, et al. . Hoypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. Proc Natl Acad Sci USA, 1995, 92(12): 5510-5510

[2] HuangL E, GuJ, SchauM, et al. . Regulation of hypoxia inducible factor 1 alpha is mediated by an O₂-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl Acad Sci USA, 1998, 95(14): 7987-7987

[3] MaxwellP, SalnikowK. HIF-1. An Oxygen and Metal Responsive Transcription Factor. Cancer Biol Ther, 2004, 31-1

[4] GiatromanolakiA, KoukourakisMI, SivridisE, et al. . Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer, 2001, 85(6): 881-881

[5] DykinsR, CorbettI P, HenryJ A, et al. . Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemistry study using monoclonal antibody NCL-CB11. J Pathol, 1991, 163(2): 105-105

[6] ZhongH, De MarzoA M, LaughnerE, et al. . Overexpression of hypoxia inducible factor lalpha in common human cancers and their metastases. Cancer Res, 1999, 59(22): 5830-5830

[7] FerraraN, Davis-SmythT. The biology of vascular endothelial growth factor. Endocr Rev, 1997, 18(1): 4-4

[8] ForsytheJ A, JiangB H, IyerN V, et al. . Activation of vascular endothelial growth factor gene transcription by hypoxia inducible factor 1. Mol Cell Biol, 1996, 16(9): 4604-4604

[9] RyanHE, LoJ, JohnsonRS. HIF-alpha is required for solid tumor formation and embryonic vascularization. Embo J., 1998, 17(11): 3005-3005

[10] GiacciaA J, KastanM B. The complexity of P53 modulation: Emerging patterns from divergent signals. Genes Dev, 1998, 122973-2973

[11] GraeberT G, OsmanianC, JacksT, et al. . Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature, 1996, 379(6560): 88-88

[12] HauptY, MayaR, KazazA, et al. . Mdm2 promotes the rapid degradation of P53. Nature, 1997, 387(6630): 266-266

[13] KubbutatM H G, JonesS N, VousdenK H. Regulation of P53 stability by Mdm2. Nature, 1997, 387(6630): 299-299

[14] RaviR, MookerjeeB, BhujwallaZ M, et al. . Regulation of tumor angiogenesis by P53-induced degradation of hypoxia inducible factor 1α. Genes Dev, 2000, 14(1): 34-34